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Background
Bendamustine is an attractive option for the management of both de novo and relapsed
lymphomas. It is being increasingly used in the conditioning regimen for autologous stem
cell transplantation (SCT) and can be an alternative to the traditionally-used carmustine.
In this study, we aimed to determine the safety and efficacy of bendamustine in the conditioning regimen for autologous SCT in refractory/relapsed lymphomas.
Methods
We designed a descriptive study to evaluate bendamustine in combination with etoposide, cytarabine, and melphalan (BeEAM) in the conditioning regimen for autologous SCT.
Results
Fourteen patients (median age, 28 yr) with Hodgkin’s lymphoma (HL) (N=8),
non-Hodgkin’s lymphomas (NHL) (N=5), or peripheral T-cell lymphoma, not otherwise
specified (PTCL NOS) (N=1) were included in the study. A median number of 5.95×106
CD34+ cells/kg were transfused. Median times to absolute neutrophil count and platelet
engraftment were 17 days and 24 days, respectively. The 100-day transplantation mortality rate was 28% (4 patients). Eight patients (57.14%) had GII-III acute kidney injury, four
patients (28.5%) had GIII-IV hyperbilirubinemia, and twelve patients (85%) had GII-III
diarrhea. After 3 months, 37% (5 patients) and 21.4% (3 patients) demonstrated complete
response and partial response, respectively. The median follow-up was 5.5 months (15
days‒19 mo). At the final follow-up, 7 patients (50%) were alive and in CR.
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Conclusion
Our study showed that bendamustine is a potentially toxic agent in the conditioning regimen for autologous SCT, resulting in significant liver, kidney, and gastrointestinal toxicity.
Further studies are required to assess its safety and efficacy at reduced doses.
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INTRODUCTION
Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL) are highly chemotherapy-sensitive tumors.
However, there is a significant subset of patients who relapse
or who never achieve complete remission. Second line salvage chemotherapy has been shown to be very effective
in patients with chemosensitive diseases with CR rates great-

er than 50%, as observed with aggressive second line chemo
immunotherapy in relapsed diffuse large B cell lymphoma
(DLBCL) [1, 2].
However, the prognosis is usually poor with conventional
salvage regimens alone [3, 4]. High dose therapy (HDT)
followed by stem cell rescue is the treatment of choice for
patients with relapsed/refractory lymphoma. Philip et al.
[5] demonstrated a statistically significant difference in
5-year event-free survival (46% vs. 12%; P =0.001) and OS
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(53% vs. 32%; P =0.038) for patients undergoing autologous
stem cell transplantation (ASCT) and salvage chemotherapy,
respectively. With improvement in supportive care and management of toxicity resulting from the conditioning regimen,
the survival rates after ASCT are approaching 60% for B
cell lymphomas [6] and 40–70% in patients with HL [7,
8].
Carmustine, etoposide, and cytarabine with melphalan
(BEAM) is the most common conditioning regimen used
for ASCT for relapsed lymphoma. Other regimens that have
been studied include cyclophosphamide (BEAC), cyclophosphamide, carmustine, and etoposide (CBV), and cyclophosphamide-TBI (total body irradiation), but BEAM remains the preferred conditioning regimen [9, 10]. Recently,
availability of carmustine has been problematic in certain
parts of the world. Therefore, there is increasing interest
in exploring other active agents that could potentially replace
carmustine in the conditioning regimen for ASCT.
Bendamustine is an attractive option to replace carmustine
because it combines the alkylating activity of the nitrogen
mustard group with the antimetabolite activity of the purine
analog structure (benzimidazole ring). Given the uniqueness
of its chemical structure, it has a different mechanism of
action from traditional alkylating agents. Carmustine demonstrates only partial cross-resistance (in vitro) with other alkylating agents. It leads to cell death via single and double
strand DNA cross-linking, and has also been shown to activate apoptotic pathways [11]. Therefore, bendamustine has
clinical potential for treating diseases that are refractory
to alkylators. It has shown superior efficacy compared to
standard therapies for relapsed chronic lymphocytic leukemia and indolent NHL [12], and is considered a standard
first line treatment for indolent B cell lymphoma [13]. These
data make it an attractive option as part of the conditioning
regimen in ASCT.
Carmustine is not available in Pakistan. After encouraging
results from a study by Visani et al. [14] demonstrating
efficacy and manageable toxicity of cotreatment of bendamustine with etoposide, cytarabine, and melphalan, we have
been exclusively using bendamustine, cytarabine, etoposide,
and carmustine (BeEAM) as the conditioning regimen for
ASCT to treat relapsed/refractory lymphoma at our
institution. Here, we present the safety and efficacy data
from use of the BeEAM protocol from the last 2 years.
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Mobilization and conditioning regimen
Patients were mobilized with granulocyte colony stimulating factor (GCSF) (5 mg/kg, twice per day subcutaneously
for 4 days) or cyclophosphamide. Patients that received cyclophosphamide (1.5 g/m2) then received GCSF (5 mg/kg,
twice daily subcutaneously for 6 days). Patients that underwent mobilization with GCSF alone underwent scheduled
stem cell pheresis on day 4. For patients who received cyclophosphamide and GCSF mobilization, stem cells were harvested on days 5 to 7 (depending on count recovery) using
either a Cobe Spectra AutoPBSC or a COMTEC (Fresenius
Kabi, Bad Homberg, Germany) system in the default software
configuration recommended by the manufacturer. After stem
cell collection, patients received the conditioning regimen,
which consisted of bendamustine coupled with fixed doses
of etoposide, cytarabine, and melphalan (BeAM) administered in an inpatient setting. BeAM regimen was given
per standard protocols and institutional guidelines.
Hyperhydration was started on day -6, followed by bendamustine 150 mg/m2 (days -5 and -4), etoposide 150 mg/m2
(days -5 to -2), cytarabine 150 mg/m2 (days -5 to -2), and
melphalan 75 mg/m2 (day -1). Stem cell infusion was performed on day 0. All patients received granulocyte colony
stimulating factor (GCSF) from day +1.

Supportive care and monitoring
A central line was inserted in all patients. They were
admitted to a single room, and reverse barrier nursing was
practiced. All patients were given antimicrobials (levofloxacin
500 mg od or ciprofloxacin 500 mg bid), an antifungal (voriconazole 200 mg qd), and an antiviral (valacyclovir 500
mg bid) as prophylaxis starting at day -5. Blood tests were
performed per standard protocols, and blood products were
transfused to keep hemoglobin levels ＞8 g/dL and platelet
count ＞15×109. In cases in which fever developed, patients
were given intravenous broad-spectrum antibiotics.
Piperacillin tazobactam or imipenem/meropenem were given for gram negative bacilli coverage. Vancomycin was the
drug of choice for management of gram positive cocci. In
addition, amphotericin B was used when fungal infections
were suspected. Patient symptoms were assessed daily, and
physical examinations were administered during their hospital stay and as per recommendations after follow-up.

Response criteria
MATERIALS AND METHODS
Patient population
Fourteen patients with resistant/relapsed lymphomas, including both NHL and HL, were included in this study.
Patient files were retrospectively reviewed to collect data
regarding their diseases, treatments, toxicities, and outcomes.
This protocol was approved by the Ethical Review Committee
of Aga Khan Hospital, Karachi.
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Engraftment was defined as achievement of an absolute
neutrophil count of 0.5×109 per liter for 3 consecutive days.
Platelet engraftment was defined as a count of 20×109 per
liter with transfusion independence. Patients were evaluated
for response at 4 weeks after transplant, and then at day
100, at the outpatient clinic. At subsequent follow-up visits,
imaging was performed per the discretion of the treating
physicians. All toxicities were defined using the National
Cancer Institute’s Common Terminology Criteria for Adverse
Events Version 3.0 (2003). All patients were evaluated using
either computed tomography (CT) or positron emission tomography (PET) before and after ASCT.
Blood Res 2019;54:108-113.
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Statistical analysis
The primary end point was to assess the safety and efficacy
of bendamustine in the conditioning regimen for autologous
stem cell transplantation in patients with relapsed/refractory
lymphoma. The secondary objectives included assessment
of time to progression and overall survival. Statistical analysis
was performed in accordance with approved protocols. The
Kaplan-Meier method was used to estimate overall survival.
Data were analyzed using Strata 12.1 software.

RESULTS
Patient characteristics
Patient characteristics are summarized in Table 1.
Fourteen patients were included in this study. The median
age of the included patients was 28 years (range, 16–58 yr).
Eleven (78.5%) patients were males and three (21.43%) patients were females. Eight patients (57.14) had Hodgkin’s
Lymphoma, five patients (35.71%) had Diffuse Large B cell
Lymphoma, and one patient (7.14%) had peripheral T-cell
lymphoma, not otherwise specified (PTCL NOS). DHAP/

RDHAP was the most commonly used regimen as a second
line treatment (11 patients, 78.5%). Two patients (14.29%)
received RICE/ICE. Eight patients (57.14%) were in CR at
the time of transplant and six patients (42.86%) were in
partial response.

Engraftment
The median number of CD34+ cells infused was 5.95×106
cells per kilogram body weight (range, 3–17.2×106 cells per
kg body weight). No engraftment failures were noted. The
median number of days on GCSF was 24 (range, 13–40 days).
The median time to neutrophil engraftment was 17 days
(range, 14–29 days), and 24 days for platelet engraftment
(range, 13–55 days) in our cohort. The average length of
hospital stay was 20 days (range, 13–45 days).

Non-hematological toxicity
Electrolyte imbalances were a frequent complication in
our patients. Serum potassium abnormalities were the most
common with 7 patients (50%) experiencing grade III (GIII)
hyperkalemia and 7 patients (50%) experiencing GI-II
hypokalemia. Nine patients (64.28%) experienced gastrointestinal (GI) hypomagnesemia. Liver dysfunction was also
a common side effect in our cohort. Eight patients (57.14%)

Table 1. Patient characteristics.
Characteristics

N

%

Age, median
Sex
Male
Female
BMI, median
IPI
0
1
2
3
Diagnosis
Hodgkin’s lymphoma
Diffuse large B cell lymphoma
PTCL NOS
Response to initial treatment
CR
Refractory
Progressive
Response to relapse therapy
CR
PD
PR
No. of treatment prior to transplan
2
3
4
Disease status at time of transplant
CR
PR

14

28 yr

11
3
14

78.57
21.43
25.5

3
6
2
3

21.4
42.8
14.2
21.4

8
5
1

57.14
35.71
7.14

7
2
5

50.00
14.29
35.71

8
1
5

57.14
7.14
35.71

11
2
1

78.57
14.29
7.14

8
6

57.14
42.86

Abbreviations: CR, complete response; IPI, indicates international
prognostic index; PD, progressive disease; PR, partial response;
PTCL NOS, peripheral T-cell lymphoma, not otherwise specified.
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Table 2. Nonhematological toxicity.
Adverse effect
Electrolyte imbalances
Hypokalemia
Hypomagnesemia
Gastrointestinal toxicity
Mucositis
Diarrhea
Nausea/vomiting
Abdominal pain
Upper GI bleed
Lower GI bleed
Hepatotoxicity
Increase transaminases
Increase ALP
Hyperbilirubinemia
Infectious complication
Febrile neutropenia
Pneumonia
Septic shock
CMV infection
Renal toxicity
Acute kidney injury
Respiratory toxicity
Pleural effusion
Respiratory failure
Cardiotoxicity
Elevated troponins
Arrhythmia
CNS toxicity
Seizures

Grade I-II

Grade III-V

7 (50%)
10 (71.4%)

7 (50%)
1 (7.1%)

5 (35.7%)
8 (57.1%)
7 (50%)
3 (21.4%)
2 (14.2%)
1 (7.1%)

3 (21.4%)
5 (35.7%)
1 (7.1%)

1 (7.1%)
4 (28.5%)
4 (28.5%)

4 (28.5%)
13 (92.85%)
4 (28.5%)
4 (28.5%)
1 (7.1%)

5 (35.7%)

4 (28.5%)
3 (21.4%)
7 (50%)

2 (14.2%)

2 (14.2%)
1 (7.1%)

1 (7.1%)

2 (14.2%)

bloodresearch.or.kr
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had mild hyperbilirubinemia and four (28.5%) patients experienced GIII-IV toxicity. Nine patients (64.29) had acute
kidney injury, among which eight patients (57.14%) experienced GII-III toxicity. Three patients (21.4%) had GIII-IV
pleural effusion. Seven patients (50%) developed respiratory
compromise requiring O2 and NIV support. Eight (57.14%)
patients developed mucositis, of which five patients developed GI-II mucositis and three developed GIII mucositis.
Gastrointestinal toxicity was seen in all of our patients.
Twelve patients (85%) developed GII-III diarrhea during
their hospital stays. Cardiotoxicity was also observed in our
cohort. Four patients exhibited increased troponin, of which
two patients had GIII toxicity, and one patient had GIV
arrhythmia.
Febrile neutropenia with GIII-IV severity was observed
in 13 (92.86%) patients. Among these patients, nine had
fever of unknown origin, one had a lower respiratory tract
infection (LRTI), and one had both LRTI and Staphylococcus
species associated CLABSI infection. One patient had septicemia secondary to Staph epidermidis and E coli. One patient
had acinetobacter CMV pneumonitis as evidenced by tracheal cultures. Transplant-related mortality at day 100 was 28%
(Table 2).
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a high IPI score. Nine patients who had low or low to intermediate IPI, 5 (55%) and one out of three patients (33.33%)
with a high – intermediate IPI score patients in CMR at
the last follow up.
The median time to follow-up was 5.5 months (15 days
to 19 mo). At the final follow-up, 5 patients had died.
Infections and subsequent systemic complications, particularly septic shock and hospital acquired pneumonia, were
the most common cause of death in our cohort. Other causes
included meningoencephalitis and CMV pneumonitis. At
the final follow-up (median time), 7 patients (50%) remained
in complete response, 2 patients (14.3%) had relapsed, and
5 patients (35.71%) had died. The median disease-free survival was 5.96 months (range, 0.46–27.96 mo) and the median
overall survival was 5.42 months (range, 0.46–27.96 mo)
(Figs. 1, 2).

DISCUSSION

At the time of transplant, 8 patients (57.14%) were in
complete metabolic response (CMR) whereas 6 patients
(42.86%) were in PR. At day +100, 5 patients (37%) were
in complete metabolic response on PET CT imaging, 3 (21%)
patients showed partial response, and 2 patients (14%) had
refractory disease. Transplant-related mortality at day 100
was 28%. Among 8 patients who underwent ASCT in CMR,
only 2 patients remained in CR and were alive at the final
follow-up. Among 6 patients who had partial response to
ASCT, 5 patients were in CMR at evaluation and were alive
at the last follow-up.
Patients with a low to intermediate IPI score exhibited
better response and survival compared to patients who had

High-dose therapy followed by ASCT is the standard of
care and the treatment of choice for eligible patients with
chemosensitive, aggressive, relapsed NHL and HL. This treatment has been validated by the PARMA and the CORAL
studies, which demonstrated a significantly higher survival
rate of greater than 50% after high-dose chemotherapy and
autologous bone marrow transplantation than after conventional chemotherapy [15]. Despite the improved survival
rates provided by HDT/ASCT, applicability of this treatment
to all relapsing patients is limited. Several factors impacted
survival. Disease status is an important predictive factor for
survival. Transplant-related morbidity and mortality is another important determinant of outcome.
The BEAM protocol has been the conditioning regimen
of choice for ASCT since the initial report by Mills et al.
[8] published in 1995. They reported that 5-year overall
survival and progression-free survival rates were 41% and
35%, respectively, with an early procedure-related mortality

Fig. 1. Overall survival.

Fig. 2. Disease free survival.

Outcome analysis
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rate of 7%. Over the years, improvement in patient selection,
mobilization techniques, and supportive care has resulted
in survival of greater than 70%, and TRM rates less than
2% [16, 17]. A retrospective review published by Reid et
al. [18] showed a trend toward better 3-year OS and PFS
in response to an outpatient BEAM regimen compared to
an inpatient BEAM regimen. This was also accompanied
by a better toxicity profile. Furthermore mBEAM showed
good tolerability, with the most frequently observed
non-hematologic toxicity being oral mucositis, mainly of
grade I/II (47%). This tolerability was better than the BEAM
regimen [11] or variants such as FEAM5 and BeEAM [19].
Late toxicities, however, remain a serious concern. Studies
have revealed that non-infectious interstitial pneumonitis
resulting from BCNU-containing regimens was a serious
complication, reported in 16–60% of the patients, with an
associated mortality rate of 9% [8, 20]. BCNU-containing
conditioning regimens have also been associated with an
increased risk of non-relapse mortality when compared with
other regimens [19-23]. Many regimens have been tested,
and the BEAM regimen remains the standard of care despite
its known serious side effects.
Unavailability of carmustine in many parts of the world
has led to efforts to develop a conditioning regimen without
carmustine. Visani et al. [14] reported results of a Phase
I/II study using increasing doses of bendamustine (160 mg/m2,
180 mg/m2 and 200 mg/m2 given on day -7 and day -6)
with fixed doses of etoposide, cytarabine, and melphalan
(BeEAM regimen), administered as a preparative regimen
for ASCT. Forty-three patients with resistant/relapsed HL
(N=15) and NHL (N=28) were enrolled, with 9 in the phase
I and 34 in the phase II studies. No patients experienced
dose-limiting toxicity. TRM at day 100 was 0%. The follow-up period at the time of publication was 18 months,
with 81% of patients alive and disease-free at that time.
Mucositis and GI toxicity were the most commonly observed
side effects. No grade III/IV nephrotoxicity or cardiotoxicity
was reported. These encouraging results led to further studies
evaluating bendamustine as a component of the conditioning
regimen.
In a large French multicenter study (Lysa group), bendamustine was administered at a median dose of 191
mg/m2/day (range, 50–250 mg/m2/day) on days 6 and 7 with
standard doses of etoposide, melphalan, and cytarabine. The
results of this study highlighted early toxicities with bendamustine which may have been underrepresented in the
Visani study due to small sample size. One hundred seven
(28%) patients developed grade I-IV nephrotoxicity. Patients
who developed ARF were also more likely to experience
colitis, pneumonitis, cardiac arrhythmias, intensive care admission, and death. Multivariate analysis showed that creatinine level at day 1, bendamustine dose ＞160 mg/m2, and
age were independent prognostic factors for ARF. Ten percent of patients needed intensive care management, and
the toxic death rate was estimated at 5% [24]. Garciaz et
al. [25] reported increased nephrotoxicity in response to
BeAM in their patients. Nine (31%) patients developed early
Blood Res 2019;54:108-113.
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renal toxicity before the day of reinfusion, of which four
(14%) patients experienced grade 3–4 renal impairment. At
day 30, the cumulative incidence of nephrotoxicity was 48%
(17% of grade 3–4), whereas in the BEAM cohort, renal
impairment was only observed in 7% of patients (5% of
grade 3–4, P ＜0.001). As also noted by the Lysa group, patients who developed nephrotoxicity were more likely to
need admission to the intensive care unit [24% of patients
in the Lysa group vs. 10% of patients in the BEAM group
(P =0.07)]. Cardiotoxicity was also more common in the
BeAM group, with grade 2–3 cardiac toxicity observed in
10% of patients (vs. 2% in the BEAM cohort, P =0.02).
Our study showed a similar toxicity profile. Twenty-eight
percent of our patients developed grade III-IV nephrotoxicity.
In addition, we saw a higher incidence of grade II-IV colitis
and hepatotoxicity than reported in previous studies. Septic
shock and respiratory failure were observed in 28% and
50% of patients, respectively. Four patients (28%) in our
cohort died in the early transplant period as a result of
septic shock and its complications. The cause of the higher
incidence of toxic death compared to that in other similar
studies is unclear and needs further examination. One hypothesis is that higher doses of bendamustine were responsible for increased toxicity. The Lysa group reported increased toxicity at doses greater than 160 mg/m2. In our
protocol, we used 150 mg/m2 of bendamustine at days 4
and 5. Despite this dose reduction, we observed significant
toxicities. Therefore, it is our opinion the appropriate dose
and schedule of bendamustine requires further study.
In conclusion, in our retrospective analysis, we reported
a high incidence of renal and cardiac toxicity and an unusually high transplant-related mortality of 28% with bendamustine in the conditioning regimen for autologous stem
cell transplant. Therefore, bendamustine should be used with
caution. Prospective comparative studies are needed to confirm the appropriate dose and schedule of bendamustine,
and to further evaluate the toxicities noted in retrospective
studies before it is routinely adopted in clinical practice.
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